drugset / Trial / NCT00977288

A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)

NCT00977288 ↗

Phase 2 Completed 408 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will investigate the effect of MK0859 when administered alone and when in combination with atorvastatin in lowering Low Density Lipoprotein -Cholesterol (LDL-C) in Japanese patients with dyslipidemia.

Timeline

Start
2009-09
Primary completion
2010-03
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Anacetrapib Small molecule 10 mg —
Subject Anacetrapib Small molecule 40 mg —
Subject Anacetrapib Small molecule 100 mg —
Subject Anacetrapib Small molecule 300 mg —
Subject Atorvastatin Small molecule 10 mg —

Indications